Clinical trials update Esc congress 2011

Cardiovascular Drugs and Therapy

Volumn 26, Issue 1, 2012, Pages 77-84

  Rosenson, Robert ^a   Horowitz, John ^b   Kaski, Juan Carlos ^c   Krum, Henry ^d   Remme, Willem ^e  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF LONDON   (United Kingdom)

^d MONASH UNIVERSITY   (Australia)

^e Sticares Cardiovascular Research Foundation   (Netherlands)

Author keywords

ARISTOTLE; ASCOT; Clinical trials; dal PLAQUE; dal VESSEL; EMPHASIS HF; RE LY; RUBY 1; SHIFT

Indexed keywords

ACETYLSALICYLIC ACID; ANACETRAPIB; ANTIVITAMIN K; APIXABAN; ATORVASTATIN; CLOPIDOGREL; DABIGATRAN; DALCETRAPIB; DAREXABAN; EPLERENONE; GROWTH HORMONE RELEASING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IVABRADINE; PLACEBO; RIVAROXABAN; TORCETRAPIB; WARFARIN;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOKALEMIA; ISCHEMIA; PRIORITY JOURNAL; STROKE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ATRIAL FIBRILLATION; FACTOR XA; FIBRINOLYTIC AGENTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84857782423     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-012-6371-7     Document Type: Conference Paper

References (29)

1. SJ Connolly MD Ezekowitz S Yusuf, et al. 2009 Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 1139 51 19717844 10.1056/NEJMoa0905561 1:CAS:528:DC%2BD1MXhtFOjsLnN
2. L Wallentin S Yusuf MD Ezekowitz, et al. 2010 Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial Lancet 376 975 83 20801496 10.1016/S0140-6736(10) 61194-4 1:CAS:528:DC%2BC3cXhtFOnt7%2FI
3. MR Patel KW Mahaffey J Garg, et al. 2011 Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 883 91 21830957 10.1056/NEJMoa1009638 1:CAS:528:DC%2BC3MXhtFKhsLnI
4. JH Alexander RD Lopes S James, et al. 2011 Apixaban with antiplatelet therapy after acute coronary syndrome N Engl J Med 365 699 708 21780946 10.1056/NEJMoa1105819 1:CAS:528:DC%2BC3MXhtV2lu73I
5. CB Granger JH Alexander JJV McMurray, et al. 2011 Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 981 92 21870978 10.1056/NEJMoa1107039 1:CAS:528:DC%2BC3MXhtF2ms7rN
6. KAA Fox JP Piccini D Wojdyla, et al. 2011 Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment Eur Heart J 32 2387 94 21873708 10.1093/eurheartj/ehr342 1:CAS:528:DC%2BC3MXht1Oitb%2FE
7. M Cohen 2009 Oral antiplatelet therapy for acute and chronic management of NSTE ACS: Residual ischemic risk and opportunities for improvement Cardiovasc Drugs Ther 23 489 99 19890703 10.1007/s10557-009-6204-5 1:CAS:528: DC%2BC3cXjtl2hsQ%3D%3D
8. EB Hanna DL Glancy JF Saucedo 2010 Antiplatelet and anticoagulant therapies in acute coronary syndromes Cardiovasc Drugs Ther 24 61 70 20033270 10.1007/s10557-009-6212-5 1:CAS:528:DC%2BC3cXkvVyms74%3D
9. J Oldgren A Budaj CB Granger For the RE-DEEM investigators, et al. 2011 Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial Eur Heart J 32 2781 9 21551462 10.1093/eurheartj/ehr113 1:CAS:528:DC%2BC3MXhsFamt77I
10. Alexander JH, Becker RC, Bhatt DL, et al. on behalf of the APPRAISE Steering Committee and Investigators. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009;119:2877/85
11. JL Mega E Braunwald S Mohanavelu, et al. 2009 Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind phase II trial Lancet 374 29 38 19539361 10.1016/S0140-6736(09) 60738-8 1:CAS:528:DC%2BD1MXotFCgtLc%3D
12. M Heeringa D Groenendaal G Strabach, et al. 2007 Co-administration of darexaban (YM150), an oral direct factor Xa inhibitor, with acetylsalicylic acid, clopidogrel and naproxen: no evidence of clinically relevant interactions J Thromb Hemost 9 360
13. PG Steg SR Mehta JW Jukema, et al. 2011 RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome Eur Heart J 32 2541 54 21878434 10.1093/eurheartj/ehr334 1:CAS:528:DC%2BC3MXhtlaqt7rL
14. PS Sever B Dahlöf NR Poulter, et al. 2003 Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre, randomized controlled trial Lancet 361 1149 58 12686036 10.1016/S0140-6736(03)12948-0 1:CAS:528:DC%2BD3sXis1yqu7o%3D (Pubitemid 36398384)
15. PS Sever CL Chang A Gupta A Whitehouse NR Poulter On the behalf of ASCOT investigators 2011 The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K Eur Heart J 32 2525 32 21873710 10.1093/eurheartj/ehr333 1:CAS:528:DC%2BC3MXhtlaqt7rE
16. M Davidson RS Rosenson 2009 HDL therapy: The next frontier Am J Cardiol 104 10 Suppl 52E 7 19895945 10.1016/j.amjcard.2009.09.020 1:CAS:528: DC%2BD1MXhs1Wju7rF
17. PJ Barter M Caulfield M Eriksson ILLUMINATE Investigators, et al. 2007 Effects of torcetrapib in partients at high risk for coronary heart disease N Engl J Med 357 2109 22 17984165 10.1056/NEJMoa0706628 1:CAS:528: DC%2BD2sXhtlGns7bL (Pubitemid 350146106)
18. M Ranalletta KK Bierilo Y Chen, et al. 2010 Biochemical characterization of cholesteryl ester transfer protein inhibitors J Lipid Res 51 2739 52 20458119 10.1194/jlr.M007468 1:CAS:528:DC%2BC3cXhtVOltr%2FP
19. EJ Niesor C Magg N Ogawa, et al. 2010 Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta HDL formation and increases reverse cholesterol transport J Lipid Res 51 3443 54 20861162 10.1194/jlr.M008706
20. ZA Fayad V Mani M Woodward For the dal-PLAQUE Investigators, et al. 2011 Lancet 2011; Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomized clinical trial Lancet 378 1547 59 21908036 10.1016/S0140-6736(11)61383-4 1:CAS:528:DC%2BC3MXhtlyktr7P
21. RS Rosenson 2010 Functional assessment of HDL: Moving beyond static measures for risk assessment Cardiovas Drugs Ther 24 71 5 10.1007/s10557-009- 6214-3
22. F Zannad JJV McMurray H Krum For the EMPHASIS-HF Study Group, et al. 2011 Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 11 21 21073363 10.1056/NEJMoa1009492 1:CAS:528:DC%2BC3MXisValuw%3D%3D
23. B Pitt F Zannad WJ Remme For the Randomized Aldactone Evaluation Study (RALES) investigators, et al. 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure N Engl J Med 341 709 17 10471456 10.1056/NEJM199909023411001 1:CAS:528:DyaK1MXmtVyrurk%3D (Pubitemid 29407370)
24. B Pitt WJ Remme F Zannad For the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators, et al. 2003 Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 1309 21 12668699 10.1056/NEJMoa030207 1:CAS:528:DC%2BD3sXis1ehurY%3D (Pubitemid 36384098)
25. P Mulder S Barbier A Chagraoul, et al. 2004 Log-term heart rate reduction induced by the selective I(f) inhibitor ivabradine improves left ventricular function and intrinsic myocardal structure in congestive heart failure Circulation 109 1674 9 14981003 10.1161/01.CIR.0000118464.48959.1C 1:CAS:528:DC%2BD2cXisFOqsbo%3D (Pubitemid 38451726)
26. K Swedberg M Komjda M Ohm For the SHIFT investigators, et al. 2010 Ivabradine and outcomes in chronic heart failure (SHIFT); A randomised, placebo-controlled trial Lancet 376 875 85 20801500 10.1016/S0140-6736(10)61198- 1 1:CAS:528:DC%2BC3cXhtFCltrzO
27. JC Tardiff E O'Meara M Komajda On behalf of the SHIFT Investigators, et al. 2011 Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy Eur Heart J 32 2507 15 10.1093/eurheartj/ehr311
28. I Ekman O Chassany M Komajda, et al. 2011 Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: Results from the SHIFT study Eur Heart J 32 2395 404 21875859 10.1093/eurheartj/ehr343
29. E Amosova E Andrejev I Zaderey U Rudenko C Ceconi R Ferrari 2011 Efficacy of ivabradine in combination with beta-blocker versus uptitration of beta-blocker in patients with stable angina Cardiovasc Drugs Ther 25 531 7 21830063 10.1007/s10557-011-6327-3 1:CAS:528:DC%2BC3MXhsFantrvL